Longevity & AgingArtículo de investigaciónDe pago

Activating the GPER estrogen receptor restores heart mitochondrial function in diabetic, estrogen-deficient rats

In ovariectomized diabetic rats, the GPER agonist G1 raised MCU expression and improved heart mitochondrial function. Rat data only; no lifespan or human results.

jueves, 19 de noviembre de 2026 1 visualización
Publicado en J Biochem Mol Toxicol
Glowing heart muscle cell with mitochondria absorbing calcium ions through a uniporter channel, estrogen receptor on membrane

Resumen

Estrogen loss and type 2 diabetes together strain heart cells, partly by disrupting how mitochondria take up calcium. In this rat study, a drug that activates the estrogen receptor GPER (G1) increased the mitochondrial calcium uniporter (MCU) in heart tissue through a cAMP/PKA/CREB pathway. Treated animals showed higher activity of the TCA cycle enzymes PDH and α-KGDH, more mitochondrial ATP production, lower oxidative stress (MDA), higher antioxidant enzyme activity (SOD) and less caspase-3, a marker of apoptosis. The work used ovariectomized rats with diet- and streptozotcin-induced diabetes. It points to a mechanism worth watching for postmenopausal diabetic heart disease, but it is animal data, with only abstract-level detail and no human, functional-cardiac or lifespan outcomes reported.

Resumen detallado

Postmenopausal women with type 2 diabetes face elevated cardiovascular risk, and estrogen deficiency plus metabolic stress may impair how heart mitochondria handle calcium. Calcium entering mitochondria through the MCU helps drive energy production, so disrupting it could weaken heart cells over time.

Researchers tested whether activating GPER, a membrane estrogen receptor, could restore this process. Rats were ovariectomized to mimic estrogen loss, and diabetes was induced with a high-fat diet plus a single 30 mg/kg streptozotocin dose. Three groups were compared: OVX, OVX plus T2D, and OVX plus T2D treated with the GPER agonist G1.

According to the abstract, G1 increased cardiac MCU expression via the cAMP/PKA/CREB cascade. This coincided with higher activity of the TCA cycle enzymes PDH and α-KGDH and improved mitochondrial ATP production. G1 also lowered the lipid peroxidation marker MDA, raised SOD activity and reduced caspase-3 expression. Together, these are mechanistic and biochemical readouts of mitochondrial function and cell-death signaling in heart tissue.

The finding suggests a plausible pathway by which estrogen signaling through GPER supports cardiac mitochondrial resilience, and it makes GPER a target worth following for diabetic cardiomyopathy after menopause.

Caveats are substantial. This is a rat study, and the abstract gives no group sizes, doses, durations or statistics. It reports no measures of cardiac function such as ejection fraction, no clinical outcomes and no lifespan data. Claims that GPER targeting is a promising therapy for women are extrapolations. Whether the effect is causal through MCU was not clear from the abstract, and safety of GPER agonists in humans is untested here.

Hallazgos clave

  • Mechanism: G1, a GPER agonist, raised cardiac MCU expression via cAMP/PKA/CREB signaling in ovariectomized diabetic rats.
  • Mitochondrial function: G1 coincided with higher PDH and α-KGDH activity and improved mitochondrial ATP production.
  • Redox and cell death: G1 lowered MDA, raised SOD activity and suppressed caspase-3 expression in cardiac tissue.
  • Model: ovariectomized rats with high-fat diet plus streptozotocin (30 mg/kg) diabetes; three groups compared.
  • Not reported in the abstract: cardiac function, lifespan, harms or any human data.

Metodología

Preclinical rat study with three groups (OVX, OVX+T2D, OVX+T2D+G1). Type 2 diabetes was induced by high-fat diet plus single-dose streptozotocin (30 mg/kg) after ovariectomy. Endpoints were molecular and biochemical: MCU expression, signaling, TCA enzymes, ATP, MDA, SOD and caspase-3. Sample size and statistics were not available in the abstract.

Limitaciones del estudio

Only the abstract was available, so group sizes, dosing, duration and effect sizes are unknown. Outcomes are biochemical, with no reported cardiac function, survival or lifespan data, and rodent results may not translate to women. The design lacks a described non-diabetic or estrogen-replaced comparator, and causality through MCU specifically is not clear from the abstract.

¿Te ha gustado este resumen?

Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.

Introduce tu correo electrónico para suscribirte: